Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor sit amet

Biopharma was not exempt from the initial shock of a global pandemic, but the worst projections have not happened and the initial beneficiaries have now emerged.

After a near universal first quarter stumble, big and medium cap pharma companies finished the half in style, with stocks up $190bn since the end of 2019. The picture is even better for young drug developers, as the Nasdaq biotech index hit an all-time high, up 17% from January. Medtechs have found the first half of 2020 more challenging, with success or failure largely defined by their product’s ability to help in the fight against COVID-19.

Discover what has driven the remarkable turn-around for biopharma and why biotech is on track for a record year for venture finance, despite the global pandemic.

Report Highlights:

  • Biopharma has shrugged off first quarter losses to end the halfway point of 2020 ahead of 2019.
  • Eli Lilly topped the big cap share price gainers, achieving a 25% increase, but most struggled, with Pfizer (-17%) and Merck & Co (-15%) coming off worse.
  • US biotech Novavax’s $1.6bn award made it the biggest beneficiary of the US Government’s Project Warp Speed. A 1994% share price gain also saw it become the best-performing stock of 2020.
  • Five COVID-19 vaccines have generated clinical data so far, with Pfizer/Biontech’s BNT162 perceived as market favourite.
  • Gilead’s remdesivir is the frontrunner for COVID-19 treatments, having received US FDA approval under emergency use measures, despite efficacy questions.
  • Biotechs have raised more than they set out to so far in 2020, and the average IPO of $193m is a new record

Download the Report

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Mauris Interdum Vehicula

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Mauris Interdum Vehicula

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Lorem ipsum

Download our white papers

Three resources for the professionally curious

Schedule EvaluatePharma Vision demo >
Stimulus      
Daily news with expert analysis
Interviews with industry leaders
Company & product events coverage
Response      
Consensus forecasts to 2024  
Archived consensus forecasts  
Sales by indication  
Therapy area, mechanism of action, and other classifications  
Licensing deals, M&A, venture financing and IPOs  
Orphan drugs and biosimilars analysis  
Success rate benchmarks (PTRS)    
Time-in-phase benchmarks by indication    
Comprehensive product and trial level R&D costs    
Clinical trials design and outcomes    
Net Present Value calculator    
Calendar of market events and catalysts    

TESTIMONIAL